Summary
47 / 100 · Bulios Score
What speaks for it
- It could repay all its net debt from 1.9 years of operating profit.
- The price moves less than the market (beta 0.49).
What to watch
- You pay 47.3 USD for 1 USD of yearly profit, a lot for its sector.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveToday you pay 47.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 7.3%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Research and development 2.6 USD
- Sales and administration 11 USD
- Taxes and other 12 USD
- Net profit 5.1 USD
Net profit, industry median (Chemicals - Specialty) 6.0 USD
Out of every 100 USD of revenue, 5.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 13.5 years of free cash flow. Its debt is larger than its cash. The debt score is high even so.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.36%
- Paid out of profit
- 17%
You receive $0.22 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $81.13 is 34% above today's price. 80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 92%
- Service 7.7%
By region
- UNITED STATES 71%
- EMEA 29%
Product brings in 92% of revenue.
Segments in detail